GENFIT: Annual Shareholders Meeting on second convening to be held on June 30, 2020 at 3:00 pm CEST
19 Juin 2020 - 5:45PM
GENFIT: Annual Shareholders Meeting on second convening to be held
on June 30, 2020 at 3:00 pm CEST
Lille (France); Cambridge
(Massachusetts, United States) — June 19, 2020 —
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to improving the lives of
patients with metabolic and chronic liver diseases, today announced
that it published in the June 19, 2020 French legal announcements
bulletin (Bulletin des Annonces Légales Obligatoires), its
convening notice for the Annual Shareholders Meeting to be held on
Tuesday, June 30, 2020, at 3:00 pm CEST.
In accordance with the provisions of Article 4
of Ordinance No. 2020-321 of March 25, 2020, the Shareholders
Meeting on second convening will be held virtually from the
Company’s headquarters located Parc Eurasanté, 885 avenue Eugène
Avinée Loos, 59120, France, with the same agenda as the June 11,
2020 Shareholders Meeting that could not validly meet as a result
of its failure to obtain the required quorum. The resolutions that
will be submitted to the June 30, 2020 Shareholders Meeting remain
unchanged.
The second part of the second Shareholders
Meeting convening notice published in the June 19, 2020 French
legal announcements bulletin (Bulletin des Annonces Légales
Obligatoires) and available in the Investors & Media section of
the Company’s website
(https://ir.genfit.com/financial-information/shareholders-meeting)
outlines the procedures by which shareholders may participate in
the Meeting notwithstanding the exceptional measures required in
order to comply with regulatory constraints and ensure the health
and safety of our shareholders.
Shareholders who have not previously done so can
provide their voting instructions via the Internet through the
VOTACCESS platform which has been reopened as of today. The
Shareholders Meeting will be available via live audio broadcast and
a recording will be made available through the Investors section of
our website (https://ir.genfit.com) under the Events section and on
the Shareholders Meeting page under Financials.
In accordance with articles R.225-77 and
R.225-79 of the French Commercial Code, proxy forms sent to the
Company, electronic votes and voting powers given to the
shareholders meeting on first convening remain valid for the
Shareholders Meeting on second convening to be held on June 30,
2020, as long as the shares voted remain in the respective
shareholders’ accounts.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial of elafibranor in PBC. As part of GENFIT’s
comprehensive approach to clinical management of patients with
NASH, GENFIT is also developing a new, non-invasive blood-based
diagnostic test, NIS4, which, if approved, could enable easier
identification of patients with NASH. With facilities in Lille and
Paris, France, and Cambridge, MA, USA, the Company has
approximately 200 employees. GENFIT is a publicly traded company
listed on the Nasdaq Global Select Market and in compartment B of
Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT).
www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995, with respect
to GENFIT, including statements regarding the reconvening of our
shareholders meeting. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking
statements. Although the Company believes its expectations
are based on the current expectations and reasonable assumptions of
the Company’s management, these forward-looking statements are
subject to numerous known and unknown risks and uncertainties,
which could cause actual results to differ materially from those
expressed in, or implied or projected by, the forward-looking
statements. These risks and uncertainties include, among other
things, the uncertainties inherent in research and development,
including related to safety, biomarkers, progression of, and
results from, its ongoing and planned clinical trials, review and
approvals by regulatory authorities of its drug and diagnostic
candidates and the Company’s continued ability to raise capital to
fund its development, as well as those risks and uncertainties
discussed or identified in the Company’s public filings with the
French Autorité des marchés financiers (“AMF”), including those
listed in Section 2.1 “Main Risks and Uncertainties” of the
Company’s 2019 Universal Registration Document filed with the AMF
on May 27, 2020 under n° D.20-0503, which is available on GENFIT’s
website (www.genfit.com) and on the website of the AMF
(www.amf-france.org) and public filings and reports filed with the
U.S. Securities and Exchange Commission (“SEC”), including the
Company’s 20-F dated May 27, 2020. In addition, even if the
Company’s results, performance, financial condition and liquidity,
and the development of the industry in which it operates are
consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods.
These forward-looking statements speak only as of the date of
publication of this document. Other than as required by applicable
law, the Company does not undertake any obligation to update or
revise any forward-looking information or statements, whether as a
result of new information, future events or otherwise.
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Annual Shareholders Meeting on second convening to be
held on June 30, 2020 at 3:00 pm CEST